The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline. Starting Sunday, Crescendo Bioscience will present a series of abstracts on its Vectra ...
Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke. A test used to predict future disease activity in patients ...
SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, announced that its Myriad Autoimmune business unit will present new data ...
Crescendo Bioscience®, Inc. has announced the online publication of results validating the performance of Vectra™ DA to measure rheumatoid arthritis (RA) disease activity in Arthritis Care & Research, ...
SALT LAKE CITY, Utah, June 10, 2014 – Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today announced that Vectra® DA data will be featured in eight posters at ...
Vectra DA is the only multi-biomarker blood test for rheumatoid arthritis (RA) disease activity that integrates the concentrations of 12 serum proteins associated with RA disease activity into a ...
Myriad Genetics, Inc. 's MYGN subsidiary, Crescendo Bioscience continues to make development with its Vectra DA assay. After last week's announcement of its contract with United Rheumatology on this ...
CareFirst BlueCross BlueShield has teamed up with Myriad Genetics to evaluate a multibiomarker rheumatoid arthritis blood test. The 18-month study will assess whether Vectra DA delivers better ...
Dec 27 (Reuters) - Myriad Genetics Inc : * Crescendo Bioscience-vectra da better than clinical inflammatory biomarkers to predict response to non-biological therapy intensification versus anti-tnf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results